European journal of neurology · 2026
1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huan Xiao, Chen Ran, Jin Lei, Wang Yuan, Xu Yafang, Yang Lei, Xi Caihua, Zheng Jianming, Luo Lijun, Yang Song, Shi Jianquan, Liu Yanping, Ruan Zhe, Wu Wanlong, Li Wei, Yue Yaoxian, Li Yarong, Jia Wenji, Zhong Huahua, Yan Chong, Song Jie, Xi Jianying, Tan Song, Jiang Qilong, Zou Zhangyu, Zhao Chongbo, Luo Sushan, Chinese Myasthenia Gravis Collaborating Group (CMGCG)
Аннотация
BACKGROUND: Myasthenic crisis (MC) affects 10%-20% of myasthenia gravis patients and is life-threatening with significant economic burden, yet its long-term outcomes remain poorly understood. This prospective multicentre study aimed to evaluate 1-year clinical outcomes after MC.
METHODS: This study enrolled patients with MC between December 2018 and October 2024 and prospectively followed at 1, 2, 3, 6, and 12 months post-MC. Outcome measures included Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) classification at 1 year after MC, all-cause mortality, and complications.
RESULTS: The cohort comprised 277 patients with 282 MC episodes with a follow-up duration of 29.16 ± 15.93 months. The in-hospital mortality was 5.05% (14/277), while the all-cause mortality was 15.16% (42/277). The leading causes of death were septic shock (35.7%) and multiple organ failure (21.4%). Among 247 patients with complete 1-year follow-up, 79.76% (197/247) achieved favorable outcomes. MG-ADL scores reduced from 21.3 ± 2.1 at baseline to 5.5 ± 1.5 at 6 months, and 2.8 ± 1.1 at 1 year post-MC (p < 0.01). Multivariable analysis identified older age at crisis (OR 1.03, p = 0.003), thymoma comorbidity (OR 1.84, p = 0.041), higher comorbidity burden (Charlson Comorbidity Index ≥ 3, OR 2.68, p = 0.003), and prolonged ICU stay (OR 1.03, p = 0.002) as independent predictors for minimal symptom expression non-responders. The most frequent chronic complications included infections (15.2%; predominantly fungal pathogens), gastrointestinal disorders (8.3%), and osteoporosis/fractures (5.1%).
CONCLUSIONS: This is the first prospective cohort study to report clinical outcomes in MG patients at post-MC stage, highlighting the importance of disease monitoring and early intervention to improve patient-centred care.
METHODS: This study enrolled patients with MC between December 2018 and October 2024 and prospectively followed at 1, 2, 3, 6, and 12 months post-MC. Outcome measures included Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) classification at 1 year after MC, all-cause mortality, and complications.
RESULTS: The cohort comprised 277 patients with 282 MC episodes with a follow-up duration of 29.16 ± 15.93 months. The in-hospital mortality was 5.05% (14/277), while the all-cause mortality was 15.16% (42/277). The leading causes of death were septic shock (35.7%) and multiple organ failure (21.4%). Among 247 patients with complete 1-year follow-up, 79.76% (197/247) achieved favorable outcomes. MG-ADL scores reduced from 21.3 ± 2.1 at baseline to 5.5 ± 1.5 at 6 months, and 2.8 ± 1.1 at 1 year post-MC (p < 0.01). Multivariable analysis identified older age at crisis (OR 1.03, p = 0.003), thymoma comorbidity (OR 1.84, p = 0.041), higher comorbidity burden (Charlson Comorbidity Index ≥ 3, OR 2.68, p = 0.003), and prolonged ICU stay (OR 1.03, p = 0.002) as independent predictors for minimal symptom expression non-responders. The most frequent chronic complications included infections (15.2%; predominantly fungal pathogens), gastrointestinal disorders (8.3%), and osteoporosis/fractures (5.1%).
CONCLUSIONS: This is the first prospective cohort study to report clinical outcomes in MG patients at post-MC stage, highlighting the importance of disease monitoring and early intervention to improve patient-centred care.